Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 2, 2008, Pages 414-420

  Sailasree, R ^a   Abhilash, A ^a   Sathyan, K M ^a   Nalinakumari, K R ^a   Thomas, Shaji ^a   Kannan, S ^a  

^a REGIONAL CANCER CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE LOCUS; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; CHI SQUARE DISTRIBUTION; DNA METHYLATION; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; POINT MUTATION; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE DELETION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 39449086075     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0284     Document Type: Article

References (27)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
2. Moore SR, Johnson NW, Pierce AM, Wilson DF. The epidemiology of mouth cancer: a review of global incidence. Oral Dis 2000;6:65-74.
3. Silverman S, Jr. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001;132:7-11S.
4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
5. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
6. Jayasurya R, Sathyan KM, Lakshminarayanan K, et al. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol 2005;18:1056-66.
7. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9.
8. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
9. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42-55.
10. Pindborg JJ, Reichart PA, Smith CJ, Vander Waal I. WHO: Histological Typing of Cancer and Precancer of the Oral Mucosa. 2nd ed. Heidelberg: Springler-Verlag; 1997.
11. Jin M, Piao Z, Kim NG, et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000;89:60-8.
12. Nakamura M, Watanabe T, Klangby U, et al. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-68.
13. Xing EP, Nie Y, Song Y, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999;5:2704-13.
14. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
15. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000;60:129-33.
16. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
17. Weber A, Bellmann U, Bootz F, Wittekin C, Tannapfel A. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch 2002;441:133-42.
18. Lopez M, Aquirre JM, Cuevas N, et al. Gene promoter hypermethylation in oral rinses of leukoplakia patients-a diagnostic and/or prognostic tool? Eur J Cancer 2003;39:2306-9.
19. Kulkarni V, Saranath D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol 2004;40:145-53.
20. Wu CL, Roz L, McKown S, et al. DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas. Genes Chromosomes Cancer 1999;25:16-25.
21. Tabach Y, Milyavsky M, Shats I, et al. The promoters of human cell cycle genes integrate signals fromtwo tumor suppressive pathways during cellular transformation. Mol Syst Biol 2005;1:2005.
22. Smeds J, Berggren P, Ma X, Xu Z, Hemminki K, Kumar R. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A p16(INK4a) and p14(ARF) and p53 genes are major targets for inactivation. Carcinogenesis 2002;23:645-55.
23. Dominguez G, Silva J, Garcia JM, et al. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res 2003;530:9-17.
24. Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 2002;8:3164-71.
25. Simon M, Voss D, Park-Simon TW, Mahlberg R, Koster G. Role of p16 and p14ARF in radio-and chemosensitivity of malignant gliomas. Oncol Rep 2006;16:127-32.
26. Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, Prieto I, Pollan M, Piris MA. P14 nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood 2002;99:1411-8.
27. Jayasurya R, Francis G, Kannan S, et al. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Int J Cancer 2004;109:710-6.